AXSM vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 02, 2026

AXSM

54.4
AI Score
VS
AXSM Wins

MRNA

51.3
AI Score

Investment Advisor Scores

AXSM

54score
Recommendation
HOLD

MRNA

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric AXSM MRNA Winner
Revenue 191.20M 534.00M MRNA
Net Income -64.54M -2.13B AXSM
Net Margin -33.8% -397.9% AXSM
Operating Income -63.36M -2.20B AXSM
ROE -118.2% -31.4% MRNA
ROA -9.0% -19.4% AXSM
Total Assets 713.61M 10.96B MRNA
Cash 305.11M 1.72B MRNA
Debt/Equity 2.16 0.09 MRNA
Current Ratio 1.39 2.29 MRNA
Free Cash Flow -20.82M -1.25B AXSM

Relative Price Performance (Last 90 Days)

AXSM 1M: -12.6% · 3M: -5.2% MRNA 1M: -30.1% · 3M: +20.8%

Current Technical Phase

AXSM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 36

RSI (14): 36.0 · Price: $211.98

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 45.3 · Price: $57.14

Fundamentals Snapshot

Metric AXSM MRNA
Market Cap
Forward P/E 36.4 -11.1
Trailing P/E
Revenue (TTM)
Revenue Growth 0.6% 0.0%
Gross Margin 0.9% -0.7%
Operating Margin -0.3% -5.6%
EPS -3.73 -7.98
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, AXSM is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.